When NASA made Scalia turn on judicial restraint

In Dissent is a recurring series by Anastasia Boden on Supreme Court dissents that have shaped (or reshaped) our country. I. The stars and your medical records When NASA’s Artemis II crew hurtled back to Earth from their ten-day mission, the four became the first to circle the moon in […]

Read More

Supreme Court to hear argument on whether corporations can be held liable as accomplices in violations of international law

Nearly 240 years ago, Congress enacted the Alien Tort Statute, which allows foreigners to bring lawsuits in U.S. courts for serious violations of international law. On Tuesday, the Supreme Court will hear oral argument in the latest attempt to define the scope of the ATS. The case, Cisco Systems v. […]

Read More

Final arguments of the term

Good morning, and welcome to what’s expected to be the final week of arguments for the 2025-26 term. Also, a reminder that the Advisory Opinions podcast is launching a newsletter that will bring information about each new AO episode right to your inbox. Sign up here. At the Court On […]

Read More

Digital location data heads back to the Supreme Court

On Monday, April 27, the Supreme Court will hear Chatrie v. United States, a case about police access to geofence data, a digital record of a person’s location. This case could serve as a landmark intervention in Fourth Amendment doctrine in the digital age – or a more limited adjustment […]

Read More

The week in review

If you’re a fan of the Advisory Opinions podcast, we’ve got exciting news to share. The Advisory Opinions newsletter, launching Tuesday, will bring information about each new AO episode right to your inbox. Sign up here. Week in Review The court heard four arguments this week, during the first half […]

Read More

Justices to consider thorny dispute between manufacturers of medication and its generic substitute

Hikma Pharmaceuticals USA v Amarin Pharma presents a complex dispute between Amarin, the manufacturer of Vascepa, a prescription medication to reduce heart disease, and Hikma, which markets a generic substitute for Vascepa. With a great deal of simplification, the general topic is how hard it should be to hold Hikma […]

Read More